Original Article Astrocytic expression of cannabinoid type ......expressed G-protein coupled receptors in the central nervous system, rivaling the abundance of benzodiazepine, dopaminergic

Int J Clin Exp Pathol 2014;7(6):2825-2837www.ijcep.com /ISSN:1936-2625/IJCEP0000390

Original Article Astrocytic expression of cannabinoid type 1 receptor in rat and human sclerotic hippocampi

Xian-Dong Meng1,2*, Dong Wei1*, Juan Li1,3*, Jun-Jun Kang4, Chen Wu1, Lei Ma1, Feng Yang1, Ge-Min Zhu1, Tang-Peng Ou-Yang1, Ying-Ying Liu4, Wen Jiang1

1Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China; 2Department of Neurology, Lanzhou General Hospital of PLA, Lanzhou 730050, China; 3Critical Care Medicine, The Affiliated Guangren Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710004, PR China; 4Institute of Neurosci-ences, The Fourth Military Medical University, Xi’an 710032, China. *Equal contributors.

Received March 31, 2014; Accepted May 20, 2014; Epub May 15, 2014; Published June 1, 2014

Abstract: Cannabinoid type 1 receptor (CB1R), which is traditionally located on axon terminals, plays an important role in the pathology of epilepsy and neurodegenerative diseases by modulating synaptic transmission. Using the pilocarpine model of chronic spontaneous recurrent seizures, which mimics the main features of mesial temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) in humans, we examined the expression of CB1R in hippocam-pal astrocytes of epileptic rats. Furthermore, we also examined the expression of astrocytic CB1R in the resected hippocampi from patients with medically refractory mesial TLE. Using immunofluorescent double labeling, we found increased expression of astrocytic CB1R in hippocampi of epileptic rats, whereas expression of astrocytic CB1R was not detectable in hippocampi of saline treated animals. Furthermore, CB1R was also found in some astrocytes in sclerotic hippocampi in a subset of patients with intractable mesial TLE. Detection with immune electron microscopy showed that the expression of CB1R was increased in astrocytes of epileptic rats and modest levels of CB1R were also found on the astrocytic membrane of sclerotic hippocampi. These results suggest that increased expression of astrocytic CB1R in sclerotic hippocampi might be involved in the cellular basis of the effects of cannabinoids on epilepsy.

Keywords: Epilepsy, cannabinoid type 1 receptor, hippocampal sclerosis, astrocyte, immune electron microscopy

Introduction

Epilepsy is one of the most common neurologi-cal diseases affecting 50 million people world-wide. Although seizures are controlled success-fully with currently available antiepileptic drugs (AEDs) in most patients, current treatments are ineffective in at least 30% of cases, demon-strating a need for more research to be done to identify better treatments [1]. Normal neuronal activity is a prerequisite for proper brain func-tion. However, excessive neuronal activity may endanger individual neurons, and even entire neuronal networks. Epilepsy manifests as states of pathological hyperexcitability and hypersynchronous activity at the neuronal net-work level. The endocannabinoid system is an important neuromodulatory system involved in a plethora of physiological functions such as modulation of neurotransmitter release, regu-lation of pain perception, and cardiovascular,

gastrointestinal and liver function [2, 3]. It con-sists of cannabinoid receptors, their endoge-nous lipid ligands, and the enzymatic machin-ery for their synthesis, release, and degradation. Cannabinoid Type 1 Receptor (CB1R), which is distributed on both excitatory and inhibitory axon terminals [4], is one of the most highly expressed G-protein coupled receptors in the central nervous system, rivaling the abundance of benzodiazepine, dopaminergic and iono-tropic glutamate receptors [5]. Endocannab- inoids are released from the postsynaptic neu-rons in an activity-dependent manner, and bind to presynaptic CB1R. Through activation of CB1R, the endocannabinoid system exerts ret-rograde inhibition of neurotransmitter release in the central nervous system [6], thereby mod-ulating neuronal excitability [7].

Published work regarding the effects of canna-binoids in epilepsy has been controversial.

http://www.ijcep.com

Astrocytic CB1R expression in sclerotic hippocampi

2826 Int J Clin Exp Pathol 2014;7(6):2825-2837

CB1R agonists display anti-epileptic effects in animal models of TLE [8] as well as in patients suffering from tonic-clonic seizures [9]. Furthermore, CB1Rs present on glutamatergic axon terminals were shown to exert an anticon-vulsant effect in the kainic acid model of epi-lepsy in mice [7, 10]. In line with this, CB1R antagonists are proconvulsant in already hyper-excitable networks, such as in pilocarpine treated animals [8, 11]. Conversely, proconvul-sive effects of CB1R agonists were described as well [12-14] and CB1R antagonists were shown to prevent the long-term increase in sei-zure susceptibility when applied during a par-ticular time-window [11, 15].

Some studies show that recurrent seizures may lead to an adverse reorganization of the endo-cannabinoid system and to the impairment of its naturally/endogenously protective effect [16, 17]. CB1R expression in astrocytes is much lower than in neurons, requiring the use of immune electron microscopy for detection [18]. CB1R activation in astrocytes promotes gluta-mate release [19], which can enhance neuronal excitability and play an important role in sus-taining epileptiform activity [20]. Although CB1R expression has been previously described in hippocampi during epileptogenesis [21-23], to date expression of astrocytic CB1R in the sclerotic hippocampus has not been reported.

The aim of the present study was to explore the expression of astrocytic CB1R in sclerotic hip-pocampi. Using immunofluorescent double labeling and immunohistochemical electron microscopy, we were able to detect changes in CB1R expression in astrocytes, as well as at symmetric synapses, in the sclerotic hippocam-pi of rats treated with pilocarpine. The expres-sion of astrocytic CB1R in the hippocampus of TLE patients was also examined.

Materials and methods

Animals

Male Sprague-Dawley rats weighing 210-230 g were used. Animals were housed in individual cages in a controlled environment (constant temperature, 22-25°C; humidity, 50-60%; 12/12 h light/dark cycle) with access to food and water ad libitum. All animal care proce-dures were in accordance with the guidelines of the National Institute for Health (NIH) Guide

and were approved by the Fourth Military Medical University Animal Care Committee. In addition, all efforts were made to minimize ani-mal suffering. Animals were assigned to experi-mental and control groups. Experimental rats were injected intraperitoneally with lithium chloride (127 mg/kg, Sigma, St. Louis, MO, USA) 18-20 hr prior to intraperitoneal injection of pilocarpine (30 mg/kg, Sigma, St. Louis, MO, USA). Scopolamine methyl bromide (1 mg/kg, Sigma, St. Louis, MO, USA) was administered 30 min prior to pilocarpine to reduce its periph-eral muscarinic effects. Rats were closely observed for the occurrence of limbic seizures and status epilepticus (SE) following pilocar-pine administration. Body weight-matched con-trol rats were treated in an identical manner, except that they were injected with saline instead of pilocarpine. The convulsive behav-iors of seizures were classified as follows: class I: hypoactivity, mouth and facial automatism; class II: head nodding and mastication; class III: forelimb clonus without rearing; class IV: bilateral forelimb clonus and rearing; class V: rearing and loss of posture. Seizures were ter-minated with diazepam (10 mg/kg, i.p.) when rats experienced class IV seizures for 1 h. Animals that did not reach the 4-5 stage sei-zure scores were removed from further experi-ments to diminish any bias.

Electrographic seizures were detected via skull surface electrodes implanted 2 weeks after the initial episode of SE. Briefly, under 10% Chloral Hydrate anesthesia (4 ml/kg, i.p.), the rat was placed on a stereotaxic frame, and electroen-cephalography (EEG) electrodes were implant-ed according to the brain atlas (Paxinos and Watson, 1986). Screw electrodes were placed on the skull over the left and right frontal cortex (3.5 mm A, 2.5 mm L) and occipital cortex (-5.0 mm P, 2.5 mm L). Each electrode was then sol-dered to a connector (Sun company, Beijing, China), which was fixed on the skull with self-curing acrylic resin (ADFA, Shofu Inc., Kyoto, Japan). The animals (n = 3 in each group) were allowed 7 days to recover from the surgery before the start of EEG recording. EEG was recorded eight hours a day for 7 days.

Tissue preparation

Animals were sacrificed 3 days (n = 6) and 4 weeks (n = 9) after pilocarpine or saline admin-



istration. Rats were perfused under anesthe-sia, first with physiological saline (1 min) and then with a fixative containing 0.05% glutaral-dehyde (TAAB, UK; only used for electron micro-scope) and 4% paraformaldehyde for 30 min. Six brains from each group were removed respectively 3 days and 4 weeks after treat-ment and cryoprotected in 30% sucrose in 0.1 M phosphate buffer at 4°C overnight. Coronal sections of each brain were cut at 12 μm thick-ness (CM1900, Leica, Heidelberger, Germany) and mounted on gelatin-coated slides for NeuN immunoperoxidase staining and GFAP/CB1R immunofluorescent double labeling. Three brains from 4-week pilocarpine or saline treat-ed groups were used for electron microscopy.

Case and tissue selection

Fifteen patients, 7 men (46.7%), 8 women (53.3%), mean age 25.3 ± 6.28 years, with medically refractory TLE with unilateral hippo-campal sclerosis on MRI, 8 (53.3%) with right- and 7 (46.7%) with left-hippocampal resec-tions, were included in this study. Diagnosis was established according to previously report-ed clinical and electrographic characteristics (Commission on Classification and Terminology of the International League Against Epilepsy, 1989). Patients, who did not achieve seizure control despite adequate use of at least two first-line AEDs in mono- or poly-therapy, and up to toxic levels, were qualified as medically refractory. All patients had extensive presurgi-cal evaluation including high-resolution 3.0T magnetic resonance imaging (MRI), prolonged non-invasive video-EEG recording and neuro-psychological testing consistent with unilateral hippocampal sclerosis. Patients with unilateral HS associated with additional abnormalities besides brain atrophy detected by visual inspection were excluded. All patients had undergone anterior temporal lobectomy and hippocampectomy during adulthood for the treatment of refractory TLE. After surgery, all patients were diagnosed with hippocampal sclerosis by two independent pathologists. Hippocampal tissue was dissected and fixed overnight in 10% formalin, and then was cryo-protected in 30% sucrose in 0.1 M phosphate buffer overnight at 4°C. Specimens were cut at 12 μm thickness on a cryostat (CM1900, Leica, Heidelberger, Germany) and mounted on slides coated with polylysine.

Five control patients, 4 men (80.0%), 1 woman (20.0%), mean age 32.2 ± 8.61 years, with traumatic brain injury caused by car accidents, were included in this study. All patients had undergone decompression surgery within six hours post-traumatic brain injury, and then parts of hippocampus were isolated from tis-sues resected. All specimens were fixed, dehy-drated, sliced, and stained like that of TLE patients.

This study has been approved by the ethics committee of the Fourth Military Medical University, and informed consent was given to all patients.

Immunoperoxidase histochemistry and immu-nofluorescent double labeling

For NeuN immunoperoxidase staining (n = 6; 4 weeks post-SE), sections were blocked for 2 h and then were incubated with mouse anti-NeuN (1:500; Millipore, Billerica, MA, USA, MAB377) 4°C overnight. Slides were then incubated with biotinylated goat anti-mouse IgG (1:300, Jackson, West Grove, PA, USA) and then incu-bated with avidin-biotin-peroxidase complex (ABC, 1:300, Sigma, St. Louis, MO, USA). The reaction was detected with the glucose oxi-dase-3, 3-diaminobenzidine method. For nega-tive control slides, the primary antibody was replaced with PBS.

All the prepared slices including epileptic and control rat hippocampus (n = 6; 3 days and 4 weeks post-SE) and TLE patient sclerotic hip-pocampi (n = 15) and controls (n = 5) were used for GFAP/CB1R immunofluorescent dou-ble labeling. Slices were blocked and then incu-bated overnight in mixed primary antibodies including mouse anti-GFAP (1:1000, Sigma, St Louis, USA, G3893) and rabbit anti-CB1R (1:300, Abcam, Hong Kong, ab23703). Slides were then incubated with biotinylated anti-rab-bit IgG (1:300, Vector, Burlingame, CA) for 4 h and finally incubated with donkey anti-mouse IgG conjugated with Alexa Fluor 594 (1:400, Invitrogen, Carlsbad, CA) and streptavidin-cya-nine 2 conjugate (1:500, SouthernBiotech, Birmingham, USA) for 4 h. The nuclei were labeled with DAPI (Sigma, St Louis, USA). Slides were examined with a confocal laser scanning microscope (Fluoview 1000; Olympus, Tokyo, Japan). Digital images were captured by



Fluoview application software (Olympus, Tokyo, Japan).

Immunohistochemistry for electron microscopy

The brains of epileptic rats (n = 3) and controls (n = 3) were removed and postfixed for 3 h at 4°C. Serial coronal sections of 50 μM thick-ness were prepared with a vibratome (VT

1000S; Leica, Heidelberger, Nussloch, Ger- many) for CB1R immunohistochemical labeling. The sections were placed in PBS containing 25% sucrose and 10% glycerol for 1 hr for cryo-protection. After a freeze-thaw treatment, sec-tions were immersed in PBS containing 5% BSA and 5% NGS for 4 h to block nonspecific immu-noreactivity. CB1R was detected with the immunogold-silver staining method. Sections

Figure 1. Hippocampal neurons and EEGs in control and epileptic rats. (A, B) Low magnification representative micrographs of control (A) and epileptic (B) hippocampus immunostained for NeuN. (A1-A4, B1-B4) Hippocampal subregions marked with boxes in (A) and (B) were magnified respectively. Significant neuronal loss was found in CA1 (B1) and CA4 (B4), and neurons were partially affected in CA3 (B2) and preserved in DG (B3) in sclerotic hippo-campi. (C-F) Number of NeuN positive cells in CA1 (C), CA3 (D), DG (E), and CA4 (F) regions were compared between control and sclerotic hippocampi. The bars indicate the means ± SD and *P < 0.05, significantly different from con-trol. s.o: stratum oriens; s.p: stratum pyramidale; s.r: stratum radiatum; s.l: stratum lucidum. Scale bar = 200 μm (A, B) and 20 μm (A1-A4; B1-B4). (G) Representative EEG traces in control and epileptic rats. The control showed normal EEG (top image in G), while spike waves were observed in epileptic rat (bottom image in G).



were incubated overnight with rabbit polyclonal anti-CB1R (1:300, Abcam, Hong Kong, ab23703), and then were incubated with goat anti-rabbit IgG conjugated to 1.4 nm gold grains (1:100, Nanoprobes, Stony Brook, NY) over-night. Silver enhancement was carried out in the dark with the HQ Silver Kit (Nanoprobes) for visualization of CB1R immunoreactivity. Before and after the silver enhancement step, sec-tions were rinsed several times with deionized water. Immunolabeled sections were fixed with 0.5% osmium tetroxide in 0.1 M phosphate buf-fer for 1 h, dehydrated in graded ethanol series, then in propylene oxide, and finally flat-embed-ded in Epon 812. After polymerization, sections were examined under a light microscope. The stratum radiatum of CA1 subregion was select-ed and trimmed under a stereomicroscope, and mounted onto blank resin stubs. Ultrathin sections were cut with an ultratome (Nova, LKB, Bromma, Sweden) and mounted on mesh

grids (six to eight sections/grid). The ultrathin sections were counterstained with uranylace-tate and lead citrate and observed under a JEM-1230 electron microscope (JEOL Ltd., Tokyo, Japan).

Immunohistochemistry and electron micros-copy quantification

In order to calculate the degree of cell loss a quantitative analysis was conducted. Six corre-sponding coronal sections through the hippo-campus of individual rats were selected for NeuN immunohistochemical and CB1R/GFAP immunofluorescence analysis. Each section was 180 μm apart from the next, ensuring that the same cell would not be counted twice. NeuN positive cells were counted along the cell layer (length = 500 μm) in a predefined field of the hippocampal CA1, CA3, DG and CA4 regions respectively. Both total number of astrocytes

Figure 2. Expression of astrocytic CB1R in hippocampi in control and epileptic rats four weeks after SE. (A1-H1) Low magnification images of control (A1-D1) and epileptic (E1-H1) hippocampi. (A2-H2) The magnified images of the regions marked with boxes in images (A1-H1). The representative images labeled with GFAP (red), and CB1R (green) antibodies and DAPI (blue), as well as the merged images were shown. CB1R was shown in some astrocytes (labeled with arrowheads). The images were obtained by laser-scanning confocal microscopy. s.o: stratum oriens; s.p: stratum pyramidale; s.r: stratum radiatum; s.lm: stratum lacunar moleculare; s.m: stratum moleculare. Scale bar = 100 μm (A1-H1) and 20 μm (A2-H2).



and number of CB1R-positive astrocytes were counted respectively in the fixed area (area = 5 × 104 μm2) in a predefined field of hippocam-pus. All measurements were performed by using Photoshop CS3.0 software (Adobe sys-tems Ltd, USA).

In order to analyze changes in synaptic CB1R expression, electron microscopy quantification was carried out in CA1. Serial ultrathin sections were made from the blocks from stratum radia-tum and examined under the electron micro-scope. Both symmetric and asymmetric syn-apses established by CB1R positive axon terminals were examined in the stratum radia-tum of experimental and control group hippo-campi. CB1R stained terminals were analyzed in every 10th section in order, following the rules of systematic random sampling, to avoid sampling of the same axon terminals. Photographs were taken of all terminals in a given area. To assess any changes occurring in the density of CB1R per terminal, the number of

gold particles located at the membrane of axon terminals was counted and normalized to 1 μm of the terminal’s perimeter.

Statistical analysis

Data were expressed as mean ± standard devi-ation (SD) and analyzed using two sample Student’s t-test, unless other specific statisti-cal methods were mentioned. SPSS 16.0 (SPSS Inc, IL, USA) was used for the statistical analy-sis and differences were considered statisti-cally significant when the P-value was <0.05.

Results

Behavior during SE and spontaneous convul-sions (SCs)

About 5 min after pilocarpine injection, all rats developed diarrhea, piloerection, and other signs of cholinergic stimulation. In the following 10 to 20 min, the rats exhibited head bobbing,

Figure 3. Expression of astrocytic CB1R in hippocampi of rats three days after SE. (A1-D1) Low magnification im-ages. (A2-D2, A3-D3) The magnified images of the regions marked with boxes in images (A1-D1). The representative images labeled with GFAP (red), and CB1R (green) antibodies and DAPI (blue), as well as the merged images were shown. CB1R was shown in a few astrocytes (labeled with arrowheads) but not in other astrocytes (D2) in hippocam-pi. The images were obtained by laser-scanning confocal microscopy. s.o: stratum oriens; s.p: stratum pyramidale; s.r: stratum radiatum; s.lm: stratum lacunosum moleculare; s.m: stratum moleculare; s.g: stratum granulare. Scale bar = 100 μm (A1-D1) and 20 μm (A2-D2; A3-D3).



scratching, chewing, and exploratory behavior. Convulsive and recurrent seizures of stage 4 or higher were observed at 30-50 min after pilo-carpine injection. Four weeks after induction of SE, SCs occurred in over 90% of the rats in the pilocarpine-treated group. Animals without SCs were removed from the study.

Characteristics of sclerotic hippocampi and EEG recordings

Both neuronal loss (Figure 1B) and astrocyte proliferation (Figure 2E1, 2E2), which are the main pathological features of hippocampal sclerosis, were found in rat hippocampi 4 weeks after SE induction. Analysis of NeuN immunostaining of low-magnification images from control (Figure 1A) and epileptic (Figure 1B) rats revealed cell loss in the epileptic hip-pocampus. Higher magnification images show that the cells in the control group were arranged in neat rows in the stratum pyramidale of CA1 (Figure 1A1) and CA3 (Figure 1A2) and the granule cell layer of dentate gyrus (Figure 1A3) and scattered in the CA4 (Figure 1A4). However, four weeks after SE obvious neuronal loss was found in CA1 (Figure 1B1, 1C) and CA4 (Figure 1B4, 1F), while neurons in CA3 were only par-tially affected (Figure 1B2, 1D) and preserved in the DG (Figure 1B3, 1E). Such changes are consistent with the human classical hippocam-pal sclerosis [24, 25]. The EEG activity of pilo-carpine treated rats differed from controls. In

the pilocarpine-pretreated group, obvious spike waves were observed within 22-28 days after SE, on the contrary the control group showed normal EEG activity (Figure 1G).

CB1R expression by astrocytes in rat sclerotic hippocampi

To determine whether CB1R is expressed by astrocytes in sclerotic hippocampi, confocal laser scanning microscopy was used. In 4-week control rats, astrocytes with slender projec-tions (Figure 2A1) and CB1R positive axonal plexus (Figure 2B1) were distributed in the CA1 subregion, but CB1R was not found in astro-cytes of the hippocampus (Figure 2D2). Four weeks after SE induction, accrementition of astrocytes (Figure 2E1), disordered nucleus (Figure 2G1), and increased CB1R fluorescence intensity (Figure 2F1) were observed in scle-rotic hippocampi. Our results also indicate the presence of CB1R in many GFAP-positive cells in sclerotic hippocampi (Figure 2H2). To deter-mine the time point when astrocytic CB1R expression becomes upregulated, we observed hippocampal astrocytes 3 days after SE induc-tion. We found that astrocytes began to prolif-erate at this time point (Figure 3A1) and CB1R expression was shown in a few astrocytes (Figure 3D3), while CB1R was not found in astrocytes of the control group. Both the den-sity of astrocytes (Figure 4A) and the percent-age of CB1R-positive astrocytes (Figure 4B) 3

Figure 4. The average number of total astrocytes and the percentage of CB1R-positive astrocytes in a fixed area of CA1 region. A: The average number of total astrocytes was compared among three days, four weeks, and controls after SE induction. B: The percentage of CB1R positive astrocytes in CA1 was compared between three days and four weeks after SE. The bars indicate the means ± SD and statistics were calculated with analysis of variance (*P < 0.05).



days after SE induction were less than in hip-pocampi examined 4 weeks after SE. No signifi-cant differences either in behavioral or mor-phometric parameters were found between 3-day and 4-week control rats, so to simplify images, only the 4-week control images are shown.

CB1R expression by astrocytes in human scle-rotic hippocampi

CB1R was found in some hippocampal astro-cytes of 9 cases of TLE patients (Figure 5L1)

and the percentage of CB1R positive astrocytes was 35.50% ± 12.36% for the 9 patients, while CB1R was not found in astrocytes of the other 6 cases of TLE patients (Figure 5H1) and 5 cases of controls (Figure 5D1). CB1R found at synapses around astrocytes, in both control and TLE patient hippocampus (Figure 5B, 5F, 5J), was distributed in a reticular pattern that was similar to that in rats, and their fluores-cence intensity on synapses was much higher than that in astrocytes (Figure 5D1, 5H1, 5L1). Because the resected hippocampal tissue from

Figure 5. Expression of astrocytic CB1R in hippocampi from TLE patients. (A-L) Fluorescent images of control (A-D) and TLE (E-L) hippocampus. (A1-L1) The magnified images of the regions marked with boxes in images (A-L). The representative images labeled with GFAP (red), and CB1R (green) antibodies and DAPI (blue), as well as the merged images were shown. CB1R was shown in some astrocytes (labeled with arrowheads). CON: control (n = 5); TLE-AST-CB1R-Negative: CB1R is negative in astrocytes in some TLE patients (n = 6); TLE-AST-CB1R-Positive: CB1R is posi-tive in astrocytes in other TLE patients (n = 9); the images were obtained by laser-scanning confocal microscopy. Scale bar = 50 μm (A-L) and 10 μm (A1-L1).



patients is incomplete, hippocampal subfields could not be distinguished.

Ultrastructural analysis of CB1R distribution in rat sclerotic hippocampi

We then examined the precise subcellular localization of CB1R in the stratum radiatum of the CA1 subregion by using silver enhanced immunogold electron microscopy. CB1R was not found in astrocytes in control tissue (Figure 6A), but sclerotic hippocampi exhibited numer-ous hypertrophic astrocytes that were positive for CB1R staining (Figure 6B), and some silver grains were also found in astrocytic mem-

branes (Figure 6C). In both control and epilep-tic tissue, most of the CB1R labeling was seen along the cell membrane; in addition to this, more labeling was detected in inhibitory axon terminals that formed symmetrical synapses (Figure 6D, 6F) than that detected around excit-atory axon terminals forming asymmetrical syn-apses (Figure 6E, 6G). Sclerotic hippocampi were marked by a substantial increase in the silver grains in the axon terminals of symmetric synapses (Figure 6B, 6F, 6H). On the contrary, no difference was found in asymmetric synaps-es between control and sclerotic hippocampi (Figure 6G, 6I).

Figure 6. Subcellular localization of astrocytic and synaptic CB1R in rats. (A) An electron microscope image showing the absence of CB1R immunopositive silver grains in astrocytic processes in control hippocampi. (B, C) Electron microscope images showing CB1R immunopositive silver grains in astrocytes in sclerotic hippocampi. A hypertro-phic astrocyte, adjoining an axon terminal to form a symmetric synapse, was positive for CB1R staining (arrows in B) and some silver grains were seen on the membranes of astrocytes (arrows in C). (D, E) Electron microscope im-ages showing CB1R immunopositive silver grains on synapses in control. Silver grains were located on presynaptic membranes of symmetric (arrowheads in D) and asymmetric (arrows in E) synapses in control hippocampus. (F, G) Electron microscope images showing CB1R immunopositive silver grains on synapses in sclerotic hippocampi. Silver grains on presynaptic membranes of symmetric synapses increased (arrowheads in F), however those on asymmetric synapses were unchanged (arrows in G). (H, I) The number of silver grains on axon terminals forming symmetric (H) and asymmetric (I) synapses between control and sclerotic hippocampi was compared. The bars in-dicate the means ± SD and *P < 0.05, significantly different from the control. M: mitochondrion; Den: dendrite; IAT: inhibitory axon terminals; EAT: excitatory axon terminals; Sp: spine; f: filament. Scale bar = 200 nm.



Discussion

In the present study, we report the expression profile of astrocytic CB1R in sclerotic hippo-campi. The expression of astrocytic CB1R was increased in hippocampi of TLE rat models 3 days and 4 weeks after SE. Furthermore, CB1R was expressed by astrocytes in the hippocam-pus of patients with refractory temporal lobe epilepsy, associated with hippocampal sclero-sis. CB1R has previously been found mainly in GABAergic interneurons [26], especially in cho-lecystokinin-containing GABAergic interneu-rons of the hippocampus [27], and some CB1R expression has been observed in glutamatergic neurons [28, 29]. It was reported that no CB1R was expressed in hippocampal astrocytes [30]. Recently, however, some studies in the hippo-campus showed that CB1 receptors also medi-ate the activation of astrocytes [18, 19] and play an important role in sustaining epilepti-form activity [20]. Therefore identifying CB1R expression characteristics in astrocytes from sclerotic hippocampi is crucial for understand-ing the role of the endocannabinoid system in the pathophysiology of epilepsy.

In the present study, the hippocampal patholo-gy generated by the administration of pilocar-pine is reminiscent to that seen in human hip-pocampal sclerosis. Significant neuronal loss is observed in the CA1 and CA4 regions of the hippocampus 4 weeks after SE induction, con-sistent with the classical hippocampal sclero-sis of TLE patients [25]. CB1R immunoreactivity was significant in the stratum pyramidale in normal hippocampus, which was similar to what had been previously reported [22, 23, 31]. We did not find CB1R expression in astrocytes in control brain, presumably because CB1R expression in astrocytes was below detection threshold. However, four weeks after SE induc-tion, the expression of astrocytic CB1R was sig-nificantly increased compared with control; moreover, CB1R expression was found in a few reactive astrocytes as early as the third day after SE. To identify the specific localization of CB1R, we carried out an ultrastructural exami-nation of astrocytes in hippocampal CA1 region, a region largely affected by seizures [32], and found that some CB1Rs were located on the astrocytic membrane. We were intrigued to find astrocytic CB1R expression in epileptic rat hip-pocampi, and were curious to see whether this

is a reflection of the human pathology. Upon examining patient hippocampal tissue, expres-sion of astrocytic CB1R was found in 9 cases of TLE patients, but it could not be detectable in another 6 cases of TLE patients and 5 cases of control. The fact that CB1R expression could not be detected in the astrocytes of all TLE patients suggested that astrocytic CB1R expression might be fluctuating in the course of TLE. It is possible that the results observed by Magloczky were due to the detection threshold of the antibody used [30]. Recently, some stud-ies reported that the activation of astrocytic CB1R induces the release of calcium from intracellular stores, which then triggers gluta-mate release and results in the potentiation of synaptic transmission in neighboring neurons [19, 33]. These effects could be enhanced with the increasing expression of CB1R in astro-cytes, which may be helpful to further under-stand the role of CB1R in epilepsy.

Because astrocytes and synapses are closely interconnected in the structure of tripartite syn-apse, astrocytes are able to exert an essential function in controlling synaptic transmission in the hippocampus [34, 35]; similarly, neuronal discharge may also induce a comparable acti-vation of astrocytic networks [36]. In the pilo-carpine model of TLE, in addition to the increased expression of astrocytic CB1R in hip-pocampal sclerotic tissue, presence of CB1R-positive axons, which covered the entire hippo-campus, was also significantly increased. Moreover this increase was mainly on the inhib-itory presynaptic membrane. GABAergic trans-mission, while physiologically inhibitory in the adult brain, can become depolarizing and even excitatory in the human epileptic temporal lobe [37]. Thus increasing expression of CB1R on the inhibitory presynaptic membrane may be an endogenous mechanism to inhibit GABA release and form a negative feedback loop to terminate seizure discharge. Actually, when GABA currents exhibit a depolarizing shift (under pathophysiological conditions), benzodi-azepines become ineffective and instead con-tribute to the overall excitation of the neuron-this is thought to be one of the causes of benzodiazepine resistance in a subset of patients [38]. However, in fact benzodiaze-pines, which strengthen the GABAergic system, are still effective in many epileptic patients with hippocampal sclerosis, and thus the increase



of CB1R on the inhibitory presynaptic mem-brane, which inhibits the GABAergic system, might promote epileptiform discharge in these patients. So whether the increased expression of CB1R on the inhibitory presynaptic mem-brane is proconvulsant or anticonvulsant becomes uncertain under conditions of hippo-campal sclerosis.

There is still no unified consensus as to wheth-er cannabinoids suppress or facilitate epilepsy, which might be related to the differences of CB1R distribution under physiological and pathological conditions. On the one hand, CB1R on the inhibitory presynaptic membrane can inhibit GABA release, thus increasing the excitability of the neuronal network; on the other hand, CB1R on the excitatory presynaptic membrane can inhibit glutamate release, thus reducing the excitability of the neuronal net-work [39]. In the present study, CB1R expres-sion was increased in astrocytes, which are very abundant in the neuronal network, in hip-pocampal sclerotic tissue. Since CB1R activa-tion in astrocytes promotes glutamate release [19], its activation could enhance synaptic transmission [33] and play an important role in sustaining the epileptiform activity [20]. Moreover, a recent report showed the exis-tence of functional CB1R signaling in human astrocytes [40], suggesting that an increased expression of astrocytic CB1R in hippocampal sclerotic tissue might be involved in the mecha-nism underlying the effects of cannabinoids on epilepsy.

Acknowledgements

We are very grateful to Shuli Liang, Professor of Department of Neurosurgery of First Affiliated Hospital of Chinese People’s Liberation Army (PLA) General Hospital for providing the human hippocampal sclerotic tissue. This work was supported by grants from the Natural Science Foundation of China (Nos. 81271432).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Ying-Ying Liu, Institute of Neurosciences, The Fourth Military Medical University, Xi’an 710032, China. Fax: 86 29 83246270; E-mail: [email protected]; Dr. Wen Jiang, Department of Neurology, Xijing Hospital,

Fourth Military Medical University, Xi’an 710032, China. Fax: 86-29-84771319; E-mail: [email protected]

References

[1] Ono T and Galanopoulou AS. Epilepsy and epi-leptic syndrome. Adv Exp Med Biol 2012; 724: 99-113.

[2] Mackie K. Signaling via CNS cannabinoid re-ceptors. Mol Cell Endocrinol 2008; 286: S60-65.

[3] Izzo AA, Borrelli F, Capasso R, Di Marzo V and Mechoulam R. Non-psychotropic plant canna-binoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-527.

[4] Katona I and Freund TF. Endocannabinoid sig-naling as a synaptic circuit breaker in neuro-logical disease. Nat Med 2008; 14: 923-930.

[5] Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-1270.

[6] Marsicano G and Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 2006; 29: 27-46.

[7] Marsicano G, Goodenough S, Monory K, Her-mann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Ro-driguez ML, Casanova E, Schutz G, Zieglgans-berger W, Di Marzo V, Behl C and Lutz B. CB1 cannabinoid receptors and on-demand de-fense against excitotoxicity. Science 2003; 302: 84-88.

[8] Wallace MJ, Blair RE, Falenski KW, Martin BR and DeLorenzo RJ. The endogenous cannabi-noid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 2003; 307: 129-137.

[9] Consroe P. Brain cannabinoid systems as tar-gets for the therapy of neurological disorders. Neurobiol Dis 1998; 5: 534-551.

[10] Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G and Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006; 51: 455-466.

[11] Chen K, Neu A, Howard AL, Foldy C, Echegoyen J, Hilgenberg L, Smith M, Mackie K and Soltesz I. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcit-ability caused by developmental seizures. J Neurosci 2007; 27: 46-58.

[12] Keeler MH and Reifler CB. Grand mal convul-sions subsequent to marijuana use. Case re-port. Dis Nerv Syst 1967; 28: 474-475.



[13] Gordon E and Devinsky O. Alcohol and mari-juana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42: 1266-1272.

[14] Lutz B. On-demand activation of the endocan-nabinoid system in the control of neuronal ex-citability and epileptiform seizures. Biochem Pharmacol 2004; 68: 1691-1698.

[15] Echegoyen J, Armstrong C, Morgan RJ and Soltesz I. Single application of a CB1 receptor antagonist rapidly following head injury pre-vents long-term hyperexcitability in a rat mod-el. Epilepsy Res 2009; 85: 123-127.

[16] Ludanyi A, Eross L, Czirjak S, Vajda J, Halasz P, Watanabe M, Palkovits M, Magloczky Z, Freund TF and Katona I. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 2008; 28: 2976-2990.

[17] Goffin K, Van Paesschen W and Van Laere K. In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal scle-rosis. Brain 2011; 134: 1033-1040.

[18] Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, Koehl M, Abrous DN, Mendizabal-Zubiaga J, Grandes P, Liu Q, Bai G, Wang W, Xiong L, Ren W, Marsicano G and Zhang X. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012; 148: 1039-1050.

[19] Navarrete M and Araque A. Endocannabinoids mediate neuron-astrocyte communication. Ne- uron 2008; 57: 883-893.

[20] Coiret G, Ster J, Grewe B, Wendling F, Helm-chen F, Gerber U and Benquet P. Neuron to as-trocyte communication via cannabinoid recep-tors is necessary for sustained epileptiform activity in rat hippocampus. PLoS One 2012; 7: e37320.

[21] Wyeth MS, Zhang N, Mody I and Houser CR. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy. J Neurosci 2010; 30: 8993-9006.

[22] Falenski KW, Blair RE, Sim-Selley LJ, Martin BR and DeLorenzo RJ. Status epilepticus causes a long-lasting redistribution of hippocampal can-nabinoid type 1 receptor expression and func-tion in the rat pilocarpine model of acquired epilepsy. Neuroscience 2007; 146: 1232-1244.

[23] Karlocai MR, Toth K, Watanabe M, Ledent C, Juhasz G, Freund TF and Magloczky Z. Redistri-bution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-in-duced epilepsy. PLoS One 2011; 6: e27196.

[24] Thom M, Liagkouras I, Elliot KJ, Martinian L, Harkness W, McEvoy A, Caboclo LO and Sisodi-ya SM. Reliability of patterns of hippocampal

sclerosis as predictors of postsurgical out-come. Epilepsia 2010; 51: 1801-1808.

[25] Jardim AP, Neves RS, Caboclo LO, Lancellotti CL, Marinho MM, Centeno RS, Cavalheiro EA, Scorza CA and Yacubian EM. Temporal lobe epilepsy with mesial temporal sclerosis: hippo-campal neuronal loss as a predictor of surgical outcome. Arq Neuropsiquiatr 2012; 70: 319-324.

[26] Hoffman AF and Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 2000; 20: 2470-2479.

[27] Tsou K, Mackie K, Sanudo-Pena MC and Walk-er JM. Cannabinoid CB1 receptors are local-ized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocam-pal formation. Neuroscience 1999; 93: 969-975.

[28] Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T and Kano M. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory pre-synaptic sites in the hippocampus and cere-bellum. J Neurosci 2006; 26: 2991-3001.

[29] Hoffman AF, Laaris N, Kawamura M, Masino SA and Lupica CR. Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 recep-tors. J Neurosci 2010; 30: 545-555.

[30] Magloczky Z, Toth K, Karlocai R, Nagy S, Eross L, Czirjak S, Vajda J, Rasonyi G, Kelemen A, Juhos V, Halasz P, Mackie K and Freund TF. Dy-namic changes of CB1-receptor expression in hippocampi of epileptic mice and humans. Epilepsia 2010; 51 Suppl 3: 115-120.

[31] Tsou K, Brown S, Sanudo-Pena MC, Mackie K and Walker JM. Immunohistochemical distri-bution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.

[32] Morgan SL and Teyler TJ. Epileptic-like activity induces multiple forms of plasticity in hippo-campal area CA1. Brain Res 2001; 917: 90-96.

[33] Navarrete M and Araque A. Endocannabinoids potentiate synaptic transmission through stim-ulation of astrocytes. Neuron 2010; 68: 113-126.

[34] Perea G, Navarrete M and Araque A. Tripartite synapses: astrocytes process and control syn-aptic information. Trends Neurosci 2009; 32: 421-431.

[35] Halassa MM and Haydon PG. Integrated brain circuits: astrocytic networks modulate neuro-nal activity and behavior. Annu Rev Physiol 2010; 72: 335-355.

[36] Rouach N, Koulakoff A, Abudara V, Willecke K and Giaume C. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 2008; 322: 1551-1555.



[37] Cohen I, Navarro V, Clemenceau S, Baulac M and Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Sci-ence 2002; 298: 1418-1421.

[38] Deeb TZ, Maguire J and Moss SJ. Possible al-terations in GABAA receptor signaling that un-derlie benzodiazepine-resistant seizures. Epi-lepsia 2012; 53 Suppl 9: 79-88.

[39] Guggenhuber S, Monory K, Lutz B and Klug-mann M. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neu-rons of the hippocampus protects against sei-zure-induced excitoxicity. PLoS One 2010; 5: e15707.

[40] Navarrete M, Perea G, Maglio L, Pastor J, Gar-cia de Sola R and Araque A. Astrocyte calcium signal and gliotransmission in human brain tis-sue. Cereb Cortex 2013; 23: 1240-1246.

Documents

Original Article Astrocytic expression of cannabinoid type ......expressed G-protein coupled receptors in the central nervous system, rivaling the abundance of benzodiazepine, dopaminergic